Nanodaru

Nanodaru is a South Korean biotechnology company specializing in the development of innovative oral drug delivery systems for macromolecules and poorly soluble drugs. Founded by Professor Youngro Byun from Seoul National University, the company utilizes a proprietary nanoparticle platform that leverages bile acid transporters to facilitate the intestinal absorption of biologics. Their primary focus includes the development of oral formulations for heparin, insulin, and GLP-1 receptor agonists. By transforming injectable treatments into oral therapies, Nanodaru aims to significantly improve patient compliance and therapeutic outcomes in chronic conditions such as thrombosis and diabetes. The company's lead candidate, an oral heparin formulation, has progressed into clinical evaluation, demonstrating the potential of their delivery technology.